The Quantellect read.As of Nov 19, 2026, 3 active firms cover Sanara Medtech Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $32.00 to $35.00, so the covering firms are broadly aligned. The average target of $34.00 sits 4% above the current $32.78. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $0.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.00
+3.7% upside
Average target across 3 active firms as of Nov 19, 2026 vs $32.79 current
Highest Target$35.00
Average Target$34.00
Lowest Target$32.00
Detailed analyst forecasts for SMTI
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate SMTI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SMTI EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.13 – $0.13 · 1 analysts · +160% YoY
Next period, 1 analysts expect Sanara Medtech Inc to earn $0.13 a share (range $0.13 – $0.13), versus $0.05 a year earlier. Full-year consensus is $0.20, growing to $0.54 the year after.
REVENUE · NEXT QUARTER
$30.4M
Range $30.4M – $30.4M · 1 analysts · +9% YoY
Revenue is expected to reach $30.4M (range $30.4M – $30.4M), +9.4% year-over-year. Full-year consensus is $115.3M, rising to $130.0M next year.
Top analysts covering Sanara Medtech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SMTI.
#1
Ross Osborn
Cantor Fitzgerald · Rank #238
Buy
$46.00+40.3% to target
Overall win rate
34%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #350
Neutral
$35.00+6.8% to target
Overall win rate
34%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$32.00-2.4% to target
Overall win rate
27%
+ Follow
#4
IZ
Ilya Zubkov
Freedom Capital Markets
Neutral
$35.00+6.8% to target
Coverage
—
+ Follow
#5
IZ
Ilya Zubkov
Freedom Broker
Buy
$35.00+6.8% to target
Coverage
—
+ Follow
SMTI stock forecast FAQ
What is SMTI's average 12-month price target?+
The 3 active firms with a live target average $34.00 for Sanara Medtech Inc over the next 12 months, ranging from a $35.00 high to a $32.00 low, as of Nov 19, 2026.
Is SMTI stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SMTI?+
The Street-high target is $35.00 (HC Wainwright & Co.), and the Street-low is $32.00 (Lake Street). The average of all 3 active-firm targets is $34.00.
How many active Wall Street firms cover SMTI?+
3 active firms have a recognized rating on Sanara Medtech Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SMTI?+
Among analysts who currently cover SMTI, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $46.00 target.
What is Sanara Medtech Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.13 – $0.13) across 1 analysts. Full-year EPS is projected at $0.20, rising to $0.54 the following year.
How much revenue is Sanara Medtech Inc expected to report next quarter?+
Consensus revenue is $30.4M (range $30.4M – $30.4M). Full-year revenue is projected at $115.3M, growing to $130.0M next year.
Have analysts been upgrading or downgrading SMTI lately?+
As of Nov 19, 2026, 2 of 3 active firms rate SMTI a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SMTI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.